UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 185

Sortiert nach

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Annals of oncology, 2006-09, Vol.17 (9), p.1379-1385

2006

Volltextzugriff (PDF)

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Investigational new drugs, 2014-12, Vol.32 (6), p.1278-1284

2014

Volltextzugriff (PDF)

Tracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy

Annals of oncology, 2018-10, Vol.29, p.viii479-viii480

2018

Volltextzugriff (PDF)

VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii439-viii439

2018

Volltextzugriff (PDF)

431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers

European journal of cancer (1990), 2014-11, Vol.50, p.142-142

2014

Volltextzugriff (PDF)

1209 IMO-2125 PLUS RIBAVIRIN GIVES SUBSTANTIAL FIRST-DOSE VIRAL LOAD REDUCTIONS, CUMULATIVE ANTI-VIRAL EFFECT, IS WELL TOLERATED IN NAIVE GENOTYPE1 HCV PATIENTS: A PHASE 1 TRIAL

Journal of hepatology, 2011-03, Vol.54, p.S478-S478

2011

Volltextzugriff (PDF)

32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS

Journal of hepatology, 2010, Vol.52, p.S14-S14

2010

Volltextzugriff (PDF)

P11.82.A TARGETING THE GLIOBLASTOMA MASTER REGULATOR C/EBPß: A PHARMACOKINETIC AND PHARMACODYNAMIC NEOADJUVANT STUDY OF ST101

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii95-ii95

2023

Volltextzugriff (PDF)

Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

European journal of cancer (1990), 2022-10, Vol.174, p.S82-S83

2022

Volltextzugriff (PDF)

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors

Annals of oncology, 2021-09, Vol.32, p.S592-S592

2021

Volltextzugriff (PDF)

Results of the European Commission Marina II Study Part II—effects of discharges of naturally occurring radioactive material

Journal of environmental radioactivity, 2004, Vol.74 (1), p.255-277

2004

Volltextzugriff (PDF)

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

European journal of cancer supplements, 2009, Vol.7 (2), p.549-550

2009

Volltextzugriff (PDF)

Preliminary assessment of current radiation doses to the population of Brodokalmak from contamination of the Techa River

Journal of environmental radioactivity, 2000-01, Vol.50 (3), p.193-206

2000

Volltextzugriff (PDF)

Results of the European Commission MARINA II study: part I—general information and effects of discharges by the nuclear industry

Journal of environmental radioactivity, 2004, Vol.74 (1), p.243-254

2004

Volltextzugriff (PDF)

Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13076-e13076

2011

Volltextzugriff (PDF)

Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2901-2908

1999

Volltextzugriff (PDF)

1338PTracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1237TiPVSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Collective dose—practical ways to estimate a dose matrix

Journal of radiological protection, 2006-06, Vol.26 (2), p.189-198

2006

Volltextzugriff (PDF)

Results of the European Commission MARINA II study: part 1 - general information and effects of discharges by the nuclear industry

Journal of environmental radioactivity, 2004-01, Vol.74 (1-3), p.243-254

2004

Volltextzugriff (PDF)

Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study

European journal of cancer supplements, 2006-03, Vol.4 (2), p.154-154

2006

Volltextzugriff (PDF)

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

Frontiers in immunology, 2022-12, Vol.13, p.1073777-1073777

2022

Volltextzugriff (PDF)

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics

Journal of hepatology, 2011-08, Vol.55 (2), p.315-321

2011

Volltextzugriff (PDF)

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(171)
Mit Volltextzugriff
(169)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Tracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy

VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status

431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers

1209 IMO-2125 PLUS RIBAVIRIN GIVES SUBSTANTIAL FIRST-DOSE VIRAL LOAD REDUCTIONS, CUMULATIVE ANTI-VIRAL EFFECT, IS WELL TOLERATED IN NAIVE GENOTYPE1 HCV PATIENTS: A PHASE 1 TRIAL

32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS

P11.82.A TARGETING THE GLIOBLASTOMA MASTER REGULATOR C/EBPß: A PHARMACOKINETIC AND PHARMACODYNAMIC NEOADJUVANT STUDY OF ST101

Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors

Results of the European Commission Marina II Study Part II—effects of discharges of naturally occurring radioactive material

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

Preliminary assessment of current radiation doses to the population of Brodokalmak from contamination of the Techa River

Results of the European Commission MARINA II study: part I—general information and effects of discharges by the nuclear industry

Supra-additive effect of IMO-4200, a novel TLR7 and TLR8 dual agonist, with rituximab and cytotoxics in preclinical models of hematologic malignancies

Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer

1338PTracking VSV-IFNβ-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: The iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy

1237TiPVSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Collective dose—practical ways to estimate a dose matrix

Results of the European Commission MARINA II study: part 1 - general information and effects of discharges by the nuclear industry

Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics

Suchergebnisse filtern